ClinicalTrials.gg
CompletedNCT06190093Updated Jul 23, 2026Results posted

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

A Phase 3 interventional study of bevacizumab and ranibizumab in Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration and Wet Macular Degeneration, sponsored by Outlook Therapeutics, Inc.. Completed at 61 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Primary conditionWet Macular DegenerationRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Wet Macular Degeneration
Why
  1. The study's listed conditions name Wet Macular Degeneration, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Outlook Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in Wet Macular Degeneration with a site in United States — 7 open to participants now, 14 under way, 7 of them phase 3. Wet Macular Degeneration · United States.

Enrollment
14th of 45
400 · median 91
Started
2024
the only one that year
Phase 3
13 of 49
1 open now
Registered
45th of 49
by date
Lead sponsor
4 of 49
Outlook Therapeutics, Inc.

Among the 49 studies in Wet Macular Degeneration with a site in United States, this one is the 14th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2024, is one of 13 in phase 3, and was the 45th registered.

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

Browse Wet Macular Degeneration studies →

Open to participants now

7 of the 49 studies in Wet Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Wet Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
  • Age-Related Macular Degeneration
  • Wet Macular Degeneration

Browse trials for

04

In context

Wet Macular Degeneration Reclassified

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

This study's enrollment of 400 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.

Browse Wet Macular Degeneration studies →

Lead sponsor

Outlook Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Compared within Wet Macular Degeneration, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active primary Subfoveal Choroidal Neovascularization lesions secondary to Age-related macular degeneration (AMD) in the study eye
  • Best corrected visual acuity of 35-75 letters read (20/32 to 20/200 Snellen equivalent)
  • Study eye must:
  • Have active leakage on Fluorescein Angiogram involving the fovea
  • Have edema involving the fovea
  • Be free of scarring, fibrosis, or atrophy involving the central foveal zone

Exclusion criteria

Exclusion Criteria:

  • Previous subfoveal focal laser photocoagulation in the study eye
  • Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization
  • Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss within 1 year
  • Active intraocular inflammation (grade trace or above) in the study eye
  • Current vitreous hemorrhage in the study eye
  • Polypoidal choroidal vasculopathy (PCV) in the study eye
  • History of idiopathic or -associated uveitis in either eye
  • Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
  • Premenopausal women not using adequate
  • Current treatment for active systemic infection
  • Known allergy to any component of the study drug or history of allergy to fluorescein , not amenable to treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    ONS-5010 bevacizumab

    Biological: bevacizumab

  • Active comparator
    ranibizumab

    Biological: ranibizumab

Interventions

  • Biologicalbevacizumab

    1.25 mg, intravitreal injection

    Also known as: ONS-5010

  • Biologicalranibizumab

    0.5mg, intravitreal injection

07

What researchers measure

Primary outcomes

  1. Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8

    BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.

    Time frame: Baseline, 8 weeks

08

Results

Posted Jun 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneONS-5010 BevacizumabRanibizumab
Started200200
Completed194199
Not completed61

Outcome measures

PrimaryEvaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8

BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.

Time frame:
Baseline, 8 weeks
Reported as:
Mean · letters
Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8
lettersONS-5010 BevacizumabRanibizumab
Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 863.0 ± 13.566.2 ± 12.6

Adverse events

Collected over from enrollment until end of follow-up, up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ONS-5010 Bevacizumab0/200 (0%)9/200 (4.5%)24/200 (12%)
Ranibizumab0/200 (0%)5/200 (2.5%)5/200 (2.5%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventONS-5010 BevacizumabRanibizumab
Acute coronary syndromeCardiac disorders1/2000/200
Coronary artery diseaseCardiac disorders1/2000/200
Myocardial infarctionCardiac disorders1/2000/200
IridocyclitisEye disorders1/2000/200
DysphagiaGastrointestinal disorders0/2001/200
Intestinal obstructionGastrointestinal disorders1/2000/200
Bile duct stoneHepatobiliary disorders1/2000/200
Cholecystitis acuteHepatobiliary disorders1/2000/200
AppendicitisInfections and infestations0/2001/200
COVID-19 pneumoniaInfections and infestations0/2001/200
Most frequent other events
Most frequent other events
EventONS-5010 BevacizumabRanibizumab
Urinary tract infectionInfections and infestations14/2003/200
HypertensionVascular disorders10/2002/200

Baseline characteristics

Age, Continuous
Age, Continuous(years)ONS-5010 BevacizumabRanibizumabTotal
Mean78.6 ± 7.7477.8 ± 7.7378.2 ± 7.73
Sex: Female, Male
Sex: Female, Male(Participants)ONS-5010 BevacizumabRanibizumabTotal
Female133115248
Male6785152
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ONS-5010 BevacizumabRanibizumabTotal
American Indian or Alaska Native011
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American538
White194195389
More than one race000
Unknown or Not Reported000
09

Study locations

61 sites
  • Clinical Site
    Arcadia, California 91006, United States
  • Clinical Site
    Bakersfield, California 93309, United States
  • Clinical Site
    Beverly Hills, California 90210, United States
  • Clinical Site
    Huntington Beach, California 92647, United States
  • Clinical Site
    Laguna Hills, California 92653, United States
  • Clinical Site
    Long Beach, California 90807, United States
  • Clinical Site
    Modesto, California 95356, United States
  • Clinical Site
    Oakland, California 94611, United States
  • Clinical Site
    Pasadena, California 91107, United States
  • Clinical Site
    Poway, California 92064, United States
  • Clinical Site
    Sacramento, California 95841, United States
  • Clinical Site
    Colorado Springs, Colorado 80909, United States
  • Clinical Site
    Lakewood, Colorado 80228, United States
  • Clinical Site
    Waterford, Connecticut 06385, United States
  • Clinical Site
    Coral Springs, Florida 33067, United States
  • Clinical Site
    Fort Lauderdale, Florida 33308, United States
  • Clinical Site
    Jacksonville, Florida 32216, United States
  • Clinical Site
    Orlando, Florida 32806, United States
  • Clinical Site
    Stuart, Florida 34994, United States
  • Clinical Site
    Oak Forest, Illinois 60452, United States
  • Clinical Site
    Oak Park, Illinois 03440, United States
  • Clinical Site
    Carmel, Indiana 46290, United States
  • Clinical Site
    Lenexa, Kansas 66215, United States
  • Clinical Site
    Lexington, Kentucky 40509, United States
  • Clinical Site
    Hagerstown, Maryland 21740, United States
  • Clinical Site
    Edina, Minnesota 55435, United States
  • Clinical Site
    Saint Louis Park, Minnesota 55416, United States
  • Clinical Site
    Jackson, Mississippi 39202, United States
  • Clinical Site
    Teaneck, New Jersey 07666, United States
  • Clinical Site
    Albuquerque, New Mexico 87109, United States
  • Clinical Site
    Liverpool, New York 13088, United States
  • Clinical Site
    Oceanside, New York 11572, United States
  • Clinical Site
    Rochester, New York 14620, United States
  • Clinical Site
    Westbury, New York 11590, United States
  • Clinical Site
    Asheville, North Carolina 28803, United States
  • Clinical Site
    Hickory, North Carolina 28602, United States
  • Clinical Site
    Wake Forest, North Carolina 27587, United States
  • Clinical Site
    Winston-Salem, North Carolina 27103, United States
  • Clinical Site
    Edmond, Oklahoma 73013, United States
  • Clinical Site
    Charleston, South Carolina 29414, United States
  • Clinical Site
    Florence, South Carolina 29501, United States
  • Clinical Site
    Ladson, South Carolina 29456, United States
  • Clinical Site
    West Columbia, South Carolina 29169, United States
  • Clinical Site
    Rapid City, South Dakota 57701, United States
  • Clinical Site
    Germantown, Tennessee 38138, United States
  • Clinical Site
    Abilene, Texas 79606, United States
  • Clinical Site
    Arlington, Texas 76012, United States
  • Clinical Site
    Austin, Texas 78705, United States
  • Clinical Site
    Beaumont, Texas 77707, United States
  • Clinical Site
    Bellaire, Texas 77401, United States
  • Clinical Site
    Dallas, Texas 75231, United States
  • Clinical Site
    Round Rock, Texas 78681, United States
  • Clinical Site
    San Antonio, Texas 78240, United States
  • Clinical Site
    San Antonio, Texas 78251, United States
  • Clinical Site
    The Woodlands, Texas 77384, United States
  • Clinical Site
    Willow Park, Texas 79606, United States
  • Clinical Site
    Salt Lake City, Utah 84107, United States
  • Clinical Site
    Fairfax, Virginia 22031, United States
  • Clinical Site
    Lynchburg, Virginia 24502, United States
  • Clinical Site
    Bellevue, Washington 98004, United States
  • Clinical Site
    Silverdale, Washington 98383, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Nov 2024, 9 months.

Results were first posted in Jun 2026, 1 year 7 months after primary completion.

Of 16 phase 3 interventional studies under Wet Macular Degeneration, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 5, 2024
StartActual
Jan 24, 2024
Primary completionActual
Nov 7, 2024
CompletionActual
Dec 5, 2024
Results first posted
Jun 30, 2026
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT06190093
Lead sponsor
Outlook Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jan 24, 2024
Primary completion
Nov 7, 2024
Completion
Dec 5, 2024
Results posted
Jun 30, 2026
Last update
Jul 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion